Skip to main
LUCD

Lucid Diagnostics (LUCD) Stock Forecast & Price Target

Lucid Diagnostics (LUCD) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lucid Diagnostics Inc. has demonstrated steady growth in the volume of EsoGuard tests, with Q3 2025 processing 2,841 tests, a 2% increase year-over-year, and projections indicate revenue growth will align closely with this increasing test volume as Medicare coverage expands. The company is enhancing its coverage from various payers, including private insurers and cash-pay plans, which is expected to accelerate revenue growth further in the latter half of 2025. Additionally, a recent positive meeting with the MolDX and CAC points to an anticipated favorable coverage decision, suggesting improved market access for the company's diagnostic offerings.

Bears say

Lucid Diagnostics Inc. reported a pro forma net loss of $10.3 million in 3Q25, which was higher than the anticipated loss of $6 million, reflecting ongoing challenges in achieving profitability. The company also underperformed in revenue, falling short of consensus expectations, highlighting potential issues with the market adoption of its products, particularly EsoGuard. Additionally, multiple risks, including dependency on insurance reimbursement and competition, further exacerbate the negative outlook on the company's financial stability and growth prospects.

Lucid Diagnostics (LUCD) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lucid Diagnostics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lucid Diagnostics (LUCD) Forecast

Analysts have given Lucid Diagnostics (LUCD) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Lucid Diagnostics (LUCD) has a Strong Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lucid Diagnostics (LUCD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.